#TRS_AUTOADD_1635472488984 P {LINE-HEIGHT: 1.5; MARGIN-TOP: 6px; FONT-FAMILY: 宋体; MARGIN-BOTTOM: 6px; FONT-SIZE: 10.5pt}#TRS_AUTOADD_1635472488984 TD {LINE-HEIGHT: 1.5; MARGIN-TOP: 6px; FONT-FAMILY: 宋体; MARGIN-BOTTOM: 6px; FONT-SIZE: 10.5pt}#TRS_AUTOADD_1635472488984 DIV {LINE-HEIGHT: 1.5; MARGIN-TOP: 6px; FONT-FAMILY: 宋体; MARGIN-BOTTOM: 6px; FONT-SIZE: 10.5pt}#TRS_AUTOADD_1635472488984 LI {LINE-HEIGHT: 1.5; MARGIN-TOP: 6px; FONT-FAMILY: 宋体; MARGIN-BOTTOM: 6px; FONT-SIZE: 10.5pt}#TRS_AUTOADD_1635472488984 {LINE-HEIGHT: 1.5; MARGIN-TOP: 6px; FONT-FAMILY: 宋体; MARGIN-BOTTOM: 6px; FONT-SIZE: 10.5pt}/**---JSON--{"p":{"font-family":"宋体","font-weight":"","font-size":"10.5pt","line-height":"1.5","direction":"","margin-top":"6px","margin-bottom":"6px","text-indent":""},"td":{"font-family":"宋体","font-weight":"","font-size":"10.5pt","line-height":"1.5","direction":"","margin-top":"6px","margin-bottom":"6px","text-indent":""},"div":{"font-family":"宋体","font-weight":"","font-size":"10.5pt","line-height":"1.5","direction":"","margin-top":"6px","margin-bottom":"6px","text-indent":""},"li":{"font-family":"宋体","font-weight":"","font-size":"10.5pt","line-height":"1.5","direction":"","margin-top":"6px","margin-bottom":"6px","text-indent":""},"":{"font-family":"宋体","font-weight":"","font-size":"10.5pt","line-height":"1.5","direction":"","margin-top":"6px","margin-bottom":"6px","text-indent":""}}--**/〔2021〕174号
牛树荟：
经查，你作为北京博晖创新生物技术集团股份有限公司（以下简称博晖创新）副总经理，于2021年9月14日在未预先披露减持计划的情况下减持博晖创新股票50,000股。
你的上述行为违反了《上市公司股东、董监高减持股份的若干规定》(证监会公告〔2017〕9号）第八条的规定。根据《上市公司股东、董监高减持股份的若干规定》（证监会公告〔2017〕9号）第十四条的规定，我局决定对你采取出具警示函的行政监管措施。
如果对本监督管理措施不服，可以在收到本决定书之日起60日内向中国证券监督管理委员会提出行政复议申请，也可以在收到本决定书之日起6个月内向有管辖权的人民法院提起诉讼。复议与诉讼期间，上述监督管理措施不停止执行。
中国证监会北京监管局
2021年10月28日
